For Clinicians | Doxycycline Uses

For Clinicians | Doxycycline Uses

Lyme Prophylaxis, Malaria Prevention, Acne, and the Doxy-PEP Debate

By Dr. Jamie Wilkey, PharmD — Director of Clinical Strategy, Jase
Medically reviewed and edited by Kristen Carpenter, PA-C

We’re continuing our series on the antibiotics we see most often come up in medical preparation conversations, one drug at a time. This week it is ….drum roll please…..doxycycline’s turn.

Doxycycline is basically the Swiss Army knife of antibiotics, except instead of a bottle opener and tiny scissors, you get malaria prevention and clearer skin. Want stellar proof? It works on Lyme disease protocol, a malaria prevention plan, an acne prescription, and now a post-exposure STI regimen. Doxycycline really does treat five unrelated problems. It isn’t that the drug just has killer marketing (although, it totally does that). It’s pharmacology: one mechanism, several targets, and, as it turns out, a guideline landscape that doesn’t fully agree on how to use it.

Take the tick bite question. The Infectious Diseases Society of America, the American Academy of Neurology, and the American College of Rheumatology all endorse a single 200 mg dose within 72 hours of a high-risk bite¹. The International Lyme and Associated Diseases Society doesn’t². Same drug and window, yet different answer depending on which guideline you’re using.

What is doxycycline used for?

More than you’d expect from one antibiotic. Doxycycline treats Lyme disease, prevents malaria, clears chlamydia, controls acne and rosacea, and, as of a 2024 CDC update³, prevents certain bacterial STIs after exposure in specific patients. 

That’s not doxycycline being a jack-of-all-trades in the vague sense. It comes down to mechanism. Doxycycline blocks protein synthesis in bacteria, the same core action tetracyclines have always had. It also disrupts a structure inside the malaria parasite called the apicoplast, a leftover organelle the parasite can’t survive without.

Quick reference: doxycycline by indication

Treatment: Lyme disease (a 10-day course performs as well as longer regimens⁴), rickettsial infections, chlamydia, and acne or rosacea.

Prevention: a single 200 mg dose within 72 hours of a high-risk tick bite, or daily dosing started before travel to a malaria-endemic area⁵.

Adjunct: reduces gum-pocket depth after periodontal treatment⁶.

Anthrax exposure: 100 mg twice daily for 60 days⁷., the CDC’s long-standing post-exposure regimen following high-risk Bacillus anthracis exposure. This one’s been on the Strategic National Stockpile for over two decades, not a new addition.

Emerging and debated: a single post-exposure dose to reduce the risk of certain bacterial STIs. That one’s newest, and it’s not settled, so it gets its own section next.

Five categories, one drug. Four of which are on well-worn clinical ground.

Where this fits into appropriate medical preparation

Three of these five uses are built for a standby kit: the single tick-bite dose, prescribed before symptoms show up; the pre-travel malaria regimen, started before a patient ever sets foot somewhere with risk; and doxycycline kept on hand ahead of a possible anthrax exposure. These work only because they’re prescribed ahead of need, not after.

That’s what we mean by appropriate medical preparation: a bounded, clinician-controlled step for conditions where the evidence is strong and the timing is predictable well in advance.

Acne, chlamydia treatment, and Doxy-PEP don’t fit that same frame. Each is answering a different clinical question, on a different timeline. None of this is a replacement for primary care. It’s the same clinical standard we’d apply at the time of symptoms, just applied earlier, for the narrow slice of doxycycline’s uses where earlier actually helps.

The bottom line

Doxycycline’s breadth isn’t hype or overuse. It has a great mechanism that allows one antibiotic to serve in several clinical roles since it blocks protein synthesis in bacteria and disrupts a different structure entirely in the malaria parasite. Most of that list is settled, well-worn clinical ground. Doxy-PEP isn’t. CDC’s 2024 guidance applies it to a defined population, adults with a bacterial STI diagnosis in the past 12 months, not sexually active adults broadly³. That population has already been redrawn once: WHO issued its own endorsement in 2026, broadly aligning with CDC, while Europe’s ECDC held back, citing resistance concerns over a population-level rollout⁸ ⁹. 

The uses that actually belong in a standby kit, prescribed ahead of need, are the tick-bite dose, pre-travel malaria regimen, and anthrax exposure backup. That’s the appropriate medical preparation slice of this list, and it’s the piece Jase is built around.

Sources

1. IDSA/AAN/ACR 2020 Lyme guideline, single 200 mg dose within 72 hours of a high-risk tick bite. Infectious Diseases Society of America. idsociety.org/practice-guideline/lyme-disease
2. ILADS treatment guidelines (the dissenting position). ilads.org/patient-care/ilads-treatment-guidelines
3. CDC Clinical Guidelines on Doxycycline Postexposure Prophylaxis, MMWR 2024. Confirms 200 mg within 72 hours, population is MSM and transgender women with a bacterial STI in the past 12 months. cdc.gov/mmwr/volumes/73/rr/rr7302a1.htm
4. Shorter versus longer antimicrobial therapy for early Lyme disease, systematic review and meta-analysis, confirming no significant difference between ≤10-day and longer courses. sciencedirect.com/science/article/abs/pii/S0732889324000440
5. CDC Yellow Book, Malaria chapter, chemoprophylaxis dosing and timing. cdc.gov/yellow-book/hcp/travel-associated-infections-diseases/malaria.html
6. Subantimicrobial-dose doxycycline (Periostat), FDA-approved 1998 as adjunct to scaling and root planing, reduces pocket depth. ncbi.nlm.nih.gov/pmc/articles/PMC6473443
7. CDC Anthrax Doxycycline Emergency Use Instructions, 100 mg twice daily for 60 days post-exposure. stacks.cdc.gov/view/cdc/56837/cdc_56837_DS1.pdf
8. WHO news release, first recommendation on doxycycline PEP, May 28, 2026. who.int/news/item/28-05-2026-who-issues-first-recommendation-on-doxycycline-post-exposure-prophylaxis
9. ECDC guidance on doxycycline for STI prevention, January 2026, recommends against population-level rollout. ecdc.europa.eu/en/news-events/ecdc-issues-guidance-doxycycline-sti-prevention